INTRODUCTION
Understanding how the immune system impacts the process of tumorigenesis has captivated some of the greatest minds in immunology for more than a century. In the 1860s, following the observation that cancer arises at sites of chronic inflammation, Rudolf Virchow proposed a tumor-promoting function for leukocytes. However, at the turn of the last century, Paul Ehrlich reasoned that protective immune responses were likely required to suppress cancer in long-lived organisms (Ehrlich, 1909) , and by the 1950s, the cancer immunosurveillance hypothesis was formally postulated to ascribe a plausible function of adaptive cellular immunity in eliminating transformed cells (Burnet, 1957; Thomas, 1959) . Indeed, studies in the past two decades have revealed both tumor-promoting inflammation and protective tumor immunity in mouse models of cancer (Grivennikov et al., 2010) . Such apparently opposing activities of inflammatory responses can be integrated into the framework of cancer immunoediting which, in its most complete manifestation, is composed of three sequential phases of tumor ''elimination,'' ''equilibrium,'' and ''escape'' (Schreiber et al., 2011) .
The original cancer immunosurveillance hypothesis attributed the role of protective tumor immunity to antigen-specific lymphocytes (Burnet, 1957; Thomas, 1959) . Studies utilizing recombination-activating gene (Rag)-deficient mice or T lymphocyte depletion antibodies have revealed increased tumor incidence or tumor outgrowth in a carcinogen-induced sarcoma model (Koebel et al., 2007; Shankaran et al., 2001 ). In addition, sarcomas that develop under conditions of immunodeficiency are more immunogenic than tumors from wild-type mice (Koebel et al., 2007; Shankaran et al., 2001) , and the dominant rejection antigen in one such tumor encodes a mutated neoepitope for CD8 + T cells (Matsushita et al., 2012) . In a genetic mouse model of sarcoma, introduction of immunogenic peptides by lentivirus infection suppresses tumor development, and the loss of antigen expression or presentation on major histocompatibility complex (MHC) I results in tumor escape from T cell attack (DuPage et al., 2012 ). These findings demonstrate that cytotoxic T cells play a critical role in restraining tumor development in response to tumor-associated foreign antigens accompanied with viral infections or mutated antigens induced by carcinogens.
Yet, tumor development does not always generate neoantigens that mediate rejection nor induce host-protective antigenspecific T cell responses. In a transgenic model of sporadic cancer, the oncogenic simian virus 40 T antigen (SV40 Tag) is somatically induced and functions as a tumor-associated neoantigen (Willimsky and Blankenstein, 2005) . However, SV40 Tag triggers CD8 + T cell tolerance and fails to reject nascent transformed cells (Willimsky and Blankenstein, 2005) . In a transgenic adenocarcinoma of mouse prostate (Tramp) model, CD8 + T cells reactive to the unmutated histone H4 peptide as a tumor-associated antigen arise spontaneously in tumorbearing mice (Savage et al., 2008) . Adoptive transfer of H4 antigen-reactive T cells into Tramp mice does not result in effector T cell differentiation (Savage et al., 2008) , which is in part due to immune repression by the regulatory cytokine transforming growth factor-b (TGF-b; Donkor et al., 2011) . These findings reveal that, although tumor antigen-specific CD8 + T cell responses are induced in oncogene-induced cancers, their activities are restrained from inducing effective cancer immunosurveillance.
The lack of host-protective, antigen-specific T cell responses implies that oncogene-induced tumors bypass the ''elimination'' and ''equilibrium'' phases of cancer immunoediting and thus may, by default, display an ''escaped'' phenotype. Since tumors are derived from normal cells, it has been postulated that tumors may not be ''foreign'' or ''dangerous'' enough to induce a protective immune response (Matzinger, 2002; Pardoll, 2003) . However, studies involving mice deficient in several immune-effector molecules have revealed signs of immunosurveillance in genetic mouse models of cancer. For instance, deficiency of the activating receptor NKG2D results in earlier tumor onset in Tramp mice (Guerra et al., 2008) . In addition, mice devoid of the cytotoxic molecule perforin (Smyth et al., 2000; Street et al., 2007) or the death receptor TNF-related apoptosis-inducing ligand (TRAIL) (Finnberg et al., 2008; Zerafa et al., 2005 ) manifest accelerated tumor growth in models of mammary carcinoma and B cell lymphoma. These observations suggest that cytotoxic immune responses are involved in repressing oncogene-induced cell transformation, although they may not engage tumor antigen-specific CD8 + T cells. Nevertheless, immunodeficiency could impair host elimination of infections (Enzler et al., 2003) , which may result in chronic inflammation and secondarily affect tumor development (Coussens and Werb, 2002; Grivennikov et al., 2010; Mantovani et al., 2008) . Whether cell transformation elicits a specific protective immune response in oncogeneinduced tumors and the nature of the potential response have not been defined. In this report, we set forth by characterizing lymphocytes with cytotoxic potential in transgenic models of murine cancer. We found that cell transformation expands a distinct group of non-circulating innate, T cell receptor (TCR)ab, and TCRgd lymphocytes that express high levels of the cytolytic molecule granzyme B and display potent cytotoxic activities against tumor cells. Generation of these lymphocytes is dependent on the cytokine IL-15, and IL-15 deficiency or overexpression results in accelerated or delayed tumor growth, respectively. These findings demonstrate that cell transformation triggers a distinct class of protective immune response by engaging unconventional tissue-resident type 1-like innate lymphoid cells and type 1 innate-like T cells.
RESULTS

Tumor Growth Elicits a Granzyme B Response in Genetic Models of Murine Cancer
To investigate whether immunosurveillance is induced in spontaneous cancers, we utilized the murine MMTV-PyMT (PyMT) mammary tumor model on the C57BL/6 background (Franklin et al., 2014) . Mammary glands from 8-week-old PyMT mice had early stage tumors, while palpable carcinomas were detected at older ages (Figures S1A and S1B). To determine whether lymphocytes with cytotoxic potential were induced in precancerous lesions, we examined expression of the cytolytic molecule granzyme B (GzmB) in leukocyte populations from the mammary glands of 8-week-old wild-type (WT) or PyMT mice. A higher percentage and number of GzmB-expressing cells were observed in PyMT mice ( Figures 1A-1C) . GzmB-producing cells in mammary tissues further expanded as tumors grew ( Figure S1C ) but were barely detectable in the spleen or mammary-tissue-draining lymph nodes of PyMT mice (Figure S1D) , revealing that the lasting GzmB response is restricted to the transformed tissue.
To determine whether the tumor-elicited GzmB response represents a general mechanism of tumor surveillance, we utilized the Tramp model of murine prostate cancer (Greenberg et al., 1995) . Compared to WT mice, a higher percentage and number of GzmB-expressing cells were present in the prostates of Tramp mice, and the cell number increased as tumors progressed to later stages (Figures S1E and S1F). GzmB-expressing cells in mammary and prostate tumors were made of heterogeneous populations of lymphocytes that could be differentiated by their surface expression of TCRb and TCRd ( Figure 1D ; data not shown). Unlike GzmB-producing TCRab + or TCRgd + T cells, TCR À GzmB + cells were negative for intracellular CD3
( Figure S1G ) and were classified as innate lymphocytes. Notably, GzmB-expressing cells from all three lineages were present in WT mice at low numbers ( Figures 1D-1F ). Cell transformation expanded all populations, with TCRab and TCRgd lineage cells proportionally more represented in PyMT mice ( Figures 1D-1F ).
GzmB-Expressing TCRab + T Cells Are Unconventional TCR À GzmB + cells from WT and PyMT mice expressed NK1.1 (Figure 2A ), a cell surface marker typically used to define conventional natural killer (cNK) cells. Notably, GzmB-producing TCRab and TCRgd lineage cells also expressed high levels of NK1.1 (Figure 2A (Zhang and Bevan, 2011) . In PyMT mice, tumor growth induces exhaustion of CD8 + T cells characterized by high expression of the inhibitory co-receptor PD-1 (Franklin et al., 2014 Figure S2G ; Table S1 ).
Notably, several conventional T cell-lineage markers, including the co-stimulatory molecules CD28 and ICOS, as well as the signal-tuning receptor CD5, were undetectable or expressed at very low levels in TCRab + NK1.1 + cells ( Figure 2E ; Table S1 , cluster 4). Furthermore, inhibitory receptors such as CTLA4 and BTLA, as well as TCR signaling molecules such as LAT, were also downregulated in TCRab + NK1.1 + cells (Table S1, Figure 3A) . participate in type 1 immune responses, but their classification has been controversial because of overlapping phenotypes (Diefenbach et al., 2014; Serafini et al., 2015) . A recent study has identified gene expression signatures for cNK cells and ILC1s by cross-referencing differentially expressed transcripts between cNK cells and ILC1s from spleen and liver (Robinette et al., 2015) . We sought to determine the identity of tumor-associated were innate lymphocytes, we validated our gating strategy by confirming that these cells expressed the Nkp46 receptor (Figure S3A) , which was considered a reliable marker for cNK cells and ILC1s (Diefenbach et al., 2014) . Transcriptome analyses showed that the signature genes of cNK cells were expressed at high levels in TCR À NK1.1 + CD49a À cells, whereas most transcripts used to define the ILC1 gene signature were enriched in TCR À NK1.1 + CD49a hi cells ( Figure 3C ; Table S2 ). In line with these observations, TCR Figure 3D ; Table S2 ). Furthermore, while both cell populations expressed comparable amounts of the transcription factor T-bet, Eomes was expressed at substantially higher levels in TCR À NK1.1 + CD49a À cells ( Figure 3D ; Table   S2 ). These findings demonstrate that the GzmB-expressing innate lymphocytes are distinct from cNK cells. One of the characteristics of conventional ILC1s is their lack of Eomes expression (Diefenbach et al., 2014; Eberl et al., 2015; Klose et al., 2014) . However, Eomes was expressed at low but detectable levels in TCR À NK1.1 + CD49a hi cells ( Figure 3D ). In addition, 10 out of 54 ILC1 signature genes were not upregulated in TCR À NK1.1 + CD49a hi cells ( Figure 3C ; Table S2 ), suggesting that they are distinct from conventional ILC1s. Indeed, CD127, encoded by the Il7r gene and considered one of the best markers for ILCs (Diefenbach et al., 2014; Serafini et al., 2015; Spits et al., 2013) , was not expressed in these cells ( Figures 3C and 3E) . Furthermore, Tnf, another ILC1 signature gene, was expressed at lower levels in TCR À NK1.1 + CD49a hi cells ( Figure 3C ; Figure 2D ), NK1.1 and PD-1 expression were mutually exclusive in TCRgd + T cells ( Figure S3D ), and only TCRgd + NK1.1 + T cells expressed high levels of GzmB ( Figure S3E ).
To further explore the likeness among the three lineages of GzmB-expressing lymphocytes, we sorted out ILC1ls, as well as cNK, TCRab Figure S4B and Table S3 ). Heat map shows data pooled from two biological replicates. Figure 4B ; Table S3 , cluster 3). Gene ontology and pathway annotation analyses showed that the gene signature was enriched for transcripts associated with cell adhesion ( Figure 4B ; Table S3 , cluster 3). Indeed, several cell adhesion molecules, including CD103, encoded by the Itgae gene, were upregulated in ILC1ls and ILTC1s, and GzmB-expressing lymphocytes from all three lineages were marked by high expression of both CD49a and CD103 ( Figure 4C ). Another shared feature of these cells was that a fraction of them expressed the inhibitory receptor Ly49E ( Figures 4D and S5D) , encoded by the Klra5 gene ( Figure 4B ), previously reported to be expressed on fetalliver-derived lymphocytes as well as intra-epithelial lymphocytes (Denning et al., 2007; Stevenaert et al., 2003; Van Beneden et al., 2002) . In addition to cell surface proteins, genes encoding several signaling molecules, transcription factors, and metabolic enzymes were all substantially upregulated in ILC1ls and ILTC1s ( Figure 4B ). Furthermore, besides Gzmb, transcripts encoding several effector molecules, including Gzmc and Tnfsf10, were enriched in ILC1ls and ILTC1s ( Figure 4B ), and the Tnfsf10-encoded cell death receptor TRAIL was expressed in all three lineages of GzmB-expressing lymphocytes ( Figure 4E ). These findings imply that ILC1ls and ILTC1s may engage multiple pathways to induce target cell cytotoxicity.
ILC1ls and ILTC1s Are Tissue-Resident and Expand in Precancerous Lesions
In addition to the upregulated gene signature, hierarchical clustering analyses revealed 122 transcripts downregulated in ILC1ls, TCRab + ILTC1s, and TCRgd + ILTC1s (Figures 5A and   S4B; Table S3 , cluster 2). Gene ontology and pathway annotation analyses showed that proteins encoded by this gene cluster were associated with signaling and cell mobility ( Figure 5A ; Table  S3 , cluster 2). Indeed, genes encoding several chemokine receptors, including Ccr2, Cx3cr1, Cxcr4, the cell trafficking receptor S1pr1, and the transcriptional regulator of cell migration Klf2, were all repressed in ILC1ls and ILTC1s ( Figure 5A , S6A, and S6B Figures 5B and 5C ). These findings demonstrate that ILC1ls and ILTC1s are tissue-resident lymphocytes, a property likely further promoted by their high expression of tissue-retention molecules such as CD103 and CD49a ( Figure 4C ). Notably, ILC1ls and ILTC1s from PyMT mice were enriched for the transcripts of Cdk6 (Figure 4B ), encoding a cyclin-dependent kinase, but had low expression of Cdkn1a (Figure 5A ), encoding the cyclin-dependent kinase inhibitor p21. We considered that cell transformation might trigger a higher proliferative capacity of ILC1ls and ILTC1s resulting in their increased numbers in PyMT mice. Indeed, ILC1ls and ILTC1s from the mammary tissue of 8-week-old PyMT mice incorporated more EdU and expressed higher levels of the cell proliferation marker Ki67 than cells from WT mice ( Figures 5D, 5E , and S6C). Together, these findings reveal that tissue-resident ILC1ls and ILTC1s selectively expand in tumors.
ILC1ls and ILTC1s Exhibit Innate Cytotoxicity toward Tumor Cells
ILC1ls and ILTC1s expressed high levels of cytolytic molecules ( Figure 4B ). To investigate the cytotoxic potential of these cells, we performed single-cell killing assays using PyMT- 6B ; Movies S1-S6). Notably, the killing triggered by ILC1ls and ILTC1s proceeded with multiple short contacts (Movies S1-S6) and appeared distinct from the stable synapse formed between antigen-specific cytotoxic T cells and their targets (Deguine et al., 2010) . These observations support that ILTC1s behave like innate lymphocytes and may not recognize peptide antigens to kill target cells. To test this hypothesis, we performed cytotoxic assays using the tumor cell line RMA-S, which lacks the transporter associated with antigen processing, a critical component of the conventional MHC Ia antigenprocessing pathway. Indeed, ILC1ls as well as TCRab + ILTC1s
and TCRgd + ILTC1s potently induced cytotoxicity of RMA-S tumor cells (Figure S7A ), supporting an innate mode of effector activities of ILTC1s.
ILC1ls and ILTC1s expressed high levels of GzmB and GzmC as well as TRAIL ( Figure 4B ), suggesting that they may utilize several effector molecules to induce target cell cytotoxicity. To investigate a role of the lytic granule pathway in target cell killing, we crossed PyMT mice to the perforindeficient background. Prf1 À/À PyMT mice had comparable numbers of ILC1ls and ILTC1s to WT PyMT mice ( Figure S7B ; data not shown). Nonetheless, perforin deficiency resulted in diminished cytolytic activities of ILC1ls and ILTC1s as well as cNKs ( Figure 6C ). These findings demonstrate that ILC1ls, ILTC1s, and cNKs predominantly engage the lytic granule pathway to kill tumor cells. Notably, Prf1 À/À PyMT mice exhibited accelerated tumor growth ( Figure 6D ), suggesting a critical function for ILC1ls, ILTC1s, and/or cNKs in cancer immunosurveillance.
IL-15, but Not Nfil3, Regulates ILC1l and ILTC1 Generation and Tumor Growth
We next sought to define a specific function for ILC1ls and ILTC1s in control of tumor development. The transcription factor Nfil3 regulates the differentiation of cNK cells (Gascoyne et al.,
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(A) Gene expression signature of the indicated cell populations sorted from pooled tumors of 20-to 24-week-old PyMT mice. Genes were manually selected from those in cluster 2 (identified by hierarchical clustering shown in Figure S4B and Table  S3 ). Heat map shows data pooled from two biological replicates.
(B-C) Flow cytometric analysis of CD45.1 (host) and CD45.2 (non-host) expression in the indicated cell populations isolated from the parabiotic PyMT mice 2 weeks after surgery (connected at 6 weeks of age). Data are representative of three independent experiments (B), and percentage of non-host chimerism was compiled from three independent experiments (C). 2009; Kamizono et al., 2009 ) and conventional ILCs (Fuchs et al., 2013; Geiger et al., 2014; Klose et al., 2014; Seillet et al., 2014) . To investigate a potential role for Nfil3 in ILC1l and ILTC1 differentiation, we first analyzed the mammary glands of Nfil3 À/À mice in the steady state. As expected, cNK cell number was greatly reduced in the absence of Nfil3 (Figure S7C) . Surprisingly, ILC1ls were unperturbed ( Figure S7C ), suggesting that differentiation of ILC1ls diverges from that of cNK cells or conventional ILCs. We further crossed PyMT mice to the Nfil3-deficient background and found that the tumor-infiltrating cNK cells were also greatly diminished ( Figure 7A ), while GzmB-expressing ILC1ls or ILTC1s from both TCRab and TCRgd lineages remained unperturbed in the tumor (Figures 7A and B ; data not shown). Importantly, Nfil3 deficiency did not affect tumor growth ( Figure 7C ), suggesting that cNK cells are dispensable for the control of tumor development in PyMT mice.
To further investigate the in vivo function of ILC1ls and ILTC1s, we followed the observation that these cells expressed high levels of the Il2rb gene encoding CD122, the b chain receptor for cytokines IL-2 and IL-15 ( Figures 7D and S5A ). These findings suggest that ILC1ls and ILTC1s may depend on IL-15 for differentiation and/or homeostasis. To test this hypothesis, we crossed PyMT mice to the IL-15-deficient background. Strikingly, IL-15 deficiency depleted ILC1ls and ILTC1s in addition to cNKs ( Figure 7E ; data not shown). Compared to control PyMT mice, Il15 À/À PyMT mice exhibited accelerated tumor growth ( Figure 7F ), developed more widespread carcinomas ( Figure S7D ), and had reduced survival ( Figure 7E ), which was in line with a recent report (Gillgrass et al., 2015) . To investigate whether IL-15 expression represents a rate-limiting step of ILC1l and ILTC1 generation, we bred PyMT mice with a strain of IL-15 transgenic (IL-15 Tg ) mice. IL-15 overexpression expanded ILC1ls and ILTC1s ( Figures 7G and S7F-S7H ) and inhibited tumor growth ( Figure 7H ). Together, these observations suggest a critical role for ILC1ls and ILTC1s, but not cNKs, in cancer immunosurveillance, although potentially redundant functions of ILC1ls, ILTC1s and cNKs cannot be excluded.
DISCUSSION
The immune system has well-defined functions in inducing immunity to foreign pathogens while maintaining tolerance to normal self-tissues. Its role in cancer, however, has been enigmatic, in part because tumors are pathogenic while at the same time self-derived. In this study, we show that cell transformation induces expansion of tissue-resident ILC1ls and ILTC1s with potent cytolytic activities against tumor cells, thus defining an unprecedented class of immune response well suited for the surveillance of nascent transformed cells.
Tumor-associated ILC1ls appear to be transcriptionally distinct but functionally related to cNK cells and, at the same time, transcriptionally related but phenotypically different from conventional CD127 + ILC1s. Recent cell-lineage tracing experiments have revealed that CD127 + ILCs and cNK cells originate from separate progenitors (Constantinides et al., 2014; Klose et al., 2014) . In line with these observations, studies using an Eomes-reporter mouse strain have demonstrated that the liver-resident CD127 + CD103 À Eomes À ILC1s, also known as liver-resident NK cells (Peng et al., 2013; Sojka et al., 2014) or immature NK cells (Takeda et al., 2005) , are a stable population and do not give rise to cNK cells in cell transfer experiments (Daussy et al., 2014) . Generation of mammary tissue ILC1ls, but not cNK cells, is independent of Nfil3, a feature shared with the ILC1-like population from the salivary gland (Cortez et al., 2014) , suggesting that ILC1ls are developmentally distinct from cNK cells as well. Intriguingly, two populations of ILC1s with differential expression of CD127 and CD103 have recently been identified in humans (Bernink et al., 2015; Bernink et al., 2013; Fuchs et al., 2013 PyMT mice monitored between 8 and 15 weeks of age (n = 7-11). Error bars represent the mean ± SEM. Two-way ANOVA was used for statistical analysis. *p < 0.05. See also Figure S7 and Movies S1-S6. (Cheroutre et al., 2011) . Recent studies have revealed that TCRab + IELs are selected by agonist antigens associated with diverse MHC specificities in the thymus (Mayans et al., 2014; McDonald et al., 2014) . Several innate-like TCRgd + T cells subsets have also been shown to require a strong TCR signal for their thymic differentiation (Wencker et al., 2014 ). Yet, upon maturation, these cells undergo attrition of TCR signaling, concomitant with acquisition of responsiveness to innate immune signals (Wencker et al., 2014) . Notably, compared to conventional tumor-associated TCRgd + and TCRab (C, F, and H) Error bars represent the mean ± SEM. Two-way ANOVA was used for statistical analysis. n.s. = not significant, *p < 0.05, **p < 0.01. See also Figure S7 .
of TCR signaling in the periphery. Defining the selection antigens for ILTC1s and the mechanisms of signal rewiring will clarify the ontogeny of ILTC1s and how they are related to IELs and other innate-like TCRgd + T cell subsets. ILC1ls and ILTC1s share a common transcriptional signature, respond similarly to tumors, and are functionally alike. Their rapid response in precancerous lesions could be attributed to their ability to sense tumor-associated stress signals such as the NKG2D ligands that are induced in transformed cells . Similar to cNK cells, ILC1ls and ILTC1s constitutively express NKG2D. Notably, the lack of cNK cells in Nfil3 À/À -deficient mice does not affect tumor growth, implying that the previously demonstrated tumor suppressor function of NKG2D (Guerra et al., 2008) may be attributed to ILC1ls and ILTC1s instead of cNK cells. In fact, although cNK cells are found in tumor tissues and exhibit cytotoxic activities against tumor cells in vitro, they do not expand in precancerous lesions. Furthermore, cNK cells are a recirculating population, which is in contrast to the tissue-resident ILC1ls and ILTC1s. Such distinct tissue localization likely makes ILC1ls and ILTC1s unique sentinels of transformed epithelium. It is interesting to note that one of the markers shared among these cell populations is the epithelial cadherin (E-cadherin) receptor CD103. CD103 interaction with E-cadherin promotes cytotoxic T cell killing of target cells (Le Floc'h et al., 2007) . Future studies will determine whether CD103 is crucial for tumor sensing and killing mediated by ILC1ls and ILTC1s.
Generation of ILC1ls and ILTC1s is dependent on the cytokine IL-15. However, it remains unknown whether IL-15 promotes their differentiation, homeostasis, and/or activation in transformed tissues. Constitutive IL-15 overexpression expands ILC1ls and ILTC1s, but the endogenous cellular sources of IL-15 involved in their regulation remain to be determined. IL-15 is expressed in epithelial cells as well as stromal cell populations and requires trans-presentation to regulate target cells (Burkett et al., 2004) . In celiac disease, intestinal epithelial cells produce excessive amounts of IL-15 to activate IELs (Jabri and Sollid, 2009 ). Interestingly, a recent study showed that deletion of the IL15 gene in colorectal cancer is associated with reduced lymphocyte proliferation concomitant with enhanced risk of tumor recurrence and poor patient outcome (Mlecnik et al., 2014) . These findings imply that secretion of IL-15 by tumor cells may promote cancer immunosurveillance. In agreement with this hypothesis, IL-15 is induced in senescent tumor cells in a transplantable tumor model and may cooperate with NKG2D to eliminate tumor cells (Iannello et al., 2013) . Nevertheless, the definitive function of tumor-produced IL-15 in cancer immunosurveillance awaits the generation of a tumor-specific, IL-15-deficient mouse model.
ILC1l-and ILTC1-associated responses are observed in two oncogene-induced murine cancer models, suggesting that they may represent a general mechanism of cancer immunosurveillance. Future studies will reveal whether the ILC1l-and ILTC1-associated responses are induced and modulated in human cancers and whether their activities can be manipulated for cancer immunotherapy.
EXPERIMENTAL PROCEDURES
Mice MMTV-PyMT mice were backcrossed to the C57BL/6 background for ten generations as previously described (Franklin et al., 2014) . Tramp, Cd1d À/À ,
Prf1
À/À , and CD45.1 + congenic mice were purchased from Jackson Laboratory. Il15 À/À mice were purchased from Taconic Farms. Nfil3 À/À mice were previously described (Kashiwada et al., 2010) and kindly provided to us by P. Rothman. IL-15 Transgenic mice were previously described (Marks-Konczalik et al., 2000) and kindly provided to us by T. Waldmann and Y. Tagaya. Littermate controls were used in all experiments when possible. All mice were bred and maintained in a specific, pathogen-free facility at MSKCC, and animal experimentation was conducted in accordance with institutional guidelines. For tumor measurement, pathology scoring, and ex vivo immune cell analyses, see Supplemental Experimental Procedures for details.
RNaseq and Transcriptome Analysis cDNA libraries were generated from RNA purified from immune cell populations, amplified using the SMARTer RACE Amplification Kit (Clontech), and sequenced in replicate for 40 million reads using 50 bp paired-end at the Integrated Genomics Operation Core Facility at MSKCC. The raw output BAM files were converted to FASTQ using PICARD. All heatmaps and PCA plots were generated using the ggplot2 package. All analyses after count table generation were conducted in the R statistical environment. For detailed analyses, see Supplemental Experimental Procedures.
Statistic Analysis
Two-tailed unpaired t test, one-way ANOVA, and two-way ANOVA were used to calculate statistical significance using Prism 6 software (GraphPad). A p value of <0.05 was considered statistically significant.
ACCESSION NUMBERS
The accession number for the RNA-seq datasets reported in this paper is GEO: GSE76362. 
SUPPLEMENTAL INFORMATION
Supplemental Information includes
